Summary
Global Markets Direct’s, ‘Sigmoid Pharma Limited - Product Pipeline Review - 2016’, provides an overview of the Sigmoid Pharma Limited’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Sigmoid Pharma Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Sigmoid Pharma Limited
- The report provides overview of Sigmoid Pharma Limited including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Sigmoid Pharma Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Sigmoid Pharma Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Sigmoid Pharma Limited’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Sigmoid Pharma Limited
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sigmoid Pharma Limited’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Sigmoid Pharma Limited Snapshot 5
Sigmoid Pharma Limited Overview 5
Key Information 5
Key Facts 5
Sigmoid Pharma Limited - Research and Development Overview 6
Key Therapeutic Areas 6
Sigmoid Pharma Limited - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Combination Treatment Modalities 10
Sigmoid Pharma Limited - Pipeline Products Glance 11
Sigmoid Pharma Limited - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Sigmoid Pharma Limited - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Sigmoid Pharma Limited - Drug Profiles 15
cyclosporine CR 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
cyclosporine 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
cyclosporine CR + cyclosporine IR 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
cyclosporine IR 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
calcitonin 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
dimethyloxalylglycine 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Helicobacter pylori [strain Hel-305] (multivalent) vaccine 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
celecoxib 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Drugs for Gastrointestinal and Immunological Disorders 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Drugs to Agonize FXR for Undisclosed Indication 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Small Molecules for Undisclosed Indication 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Sigmoid Pharma Limited - Pipeline Analysis 26
Sigmoid Pharma Limited - Pipeline Products by Target 26
Sigmoid Pharma Limited - Pipeline Products by Route of Administration 27
Sigmoid Pharma Limited - Pipeline Products by Molecule Type 28
Sigmoid Pharma Limited - Pipeline Products by Mechanism of Action 29
Sigmoid Pharma Limited - Recent Pipeline Updates 30
Sigmoid Pharma Limited - Locations And Subsidiaries 31
Head Office 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 32
Disclaimer 33
List of Tables
Sigmoid Pharma Limited, Key Information 5
Sigmoid Pharma Limited, Key Facts 5
Sigmoid Pharma Limited - Pipeline by Indication, 2016 7
Sigmoid Pharma Limited - Pipeline by Stage of Development, 2016 8
Sigmoid Pharma Limited - Monotherapy Products in Pipeline, 2016 9
Sigmoid Pharma Limited - Combination Treatment Modalities in Pipeline, 2016 10
Sigmoid Pharma Limited - Phase II, 2016 11
Sigmoid Pharma Limited - Phase I, 2016 12
Sigmoid Pharma Limited - Preclinical, 2016 13
Sigmoid Pharma Limited - Discovery, 2016 14
Sigmoid Pharma Limited - Pipeline by Target, 2016 26
Sigmoid Pharma Limited - Pipeline by Route of Administration, 2016 27
Sigmoid Pharma Limited - Pipeline by Molecule Type, 2016 28
Sigmoid Pharma Limited - Pipeline Products by Mechanism of Action, 2016 29
Sigmoid Pharma Limited - Recent Pipeline Updates, 2016 30
List of Figures
Sigmoid Pharma Limited - Pipeline by Top 10 Indication, 2016 7
Sigmoid Pharma Limited - Pipeline by Stage of Development, 2016 8
Sigmoid Pharma Limited - Monotherapy Products in Pipeline, 2016 9
Sigmoid Pharma Limited - Pipeline by Target, 2016 26
Sigmoid Pharma Limited - Pipeline by Route of Administration, 2016 27
Sigmoid Pharma Limited - Pipeline by Molecule Type, 2016 28
Sigmoid Pharma Limited - Pipeline Products by Mechanism of Action, 2016 29
